ArticleNPJ digital medicine2026
Subspecialty-specific foundation model for intelligent gastrointestinal pathology.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Gastrointestinal (GI) diseases pose a major clinical burden, yet conventional histopathology suffers from subjectivity and limited reproducibility. While existing computational pathology foundation models are often validated across many subspecialties in "broad but shallow" benchmarks, they rarely demonstrate deep clinical utility in real-world scenarios. To address this, we develop Digepath-a disease-specialized foundation model focused exclusively on high-impact GI pathology. Our approach employs a two-stage iterative optimization: first, pretraining on over 353 million multi-scale patches from 210,043 H&E-stained slides; second, fine-tuning on 471,443 expert-annotated regions, balancing tumor and non-tumor samples to enhance lesion perception amid sparse pathology in whole-slide images. Digepath achieves state-of-the-art performance on 32 of 33 systematic downstream tasks in GI pathology-including diagnosis, molecular profiling, and survival prognosis-demonstrating robust generalization. Moreover, we integrate its capabilities into an agent-based clinical reasoning framework that supports end-to-end intelligent diagnostic workflows, paving the way for real-world deployment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.